Imperial College London

DrRichardNicholas

Faculty of MedicineDepartment of Brain Sciences

Professor of Practice (Neurology)
 
 
 
//

Contact

 

r.nicholas

 
 
//

Location

 

12L12CLab BlockCharing Cross Campus

//

Summary

 

Publications

Publication Type
Year
to

224 results found

Wilkie D, Chataway J, Nicholas R, 2011, Regulation and oversight of independent investigator-led multiple sclerosis (MS) studies results in a 10-fold greater administrative workload for independent investigators compared to being an investigator in a pharmaceutical company-led MS trial, MULTIPLE SCLEROSIS JOURNAL, Vol: 17, Pages: S466-S466, ISSN: 1352-4585

Journal article

Mattoscio M, Nicholas R, Malik O, Dazzi F, Muraro PAet al., 2011, Differential increase of circulating haematopoietic stem cells following therapeutic alpha 4-integrin blockade in multiple sclerosis: definition of mobilisers versus non-mobilisers subjects and clinical correlations, MULTIPLE SCLEROSIS JOURNAL, Vol: 17, Pages: S191-S191, ISSN: 1352-4585

Journal article

Chataway J, Awad M, Meadmore K, Alsanousi A, Frost C, Chandler K, Merrick K, Wilkie D, Nicholas R, Chan Det al., 2011, COGNITIVE AND NEUROPSYCHIATRIC STATUS IN A LARGE COHORT OF PATIENTS WITH SECONDARY PROGRESSIVE MULTIPLE SCLEROSIS, JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, Vol: 82, ISSN: 0022-3050

Journal article

Howell OW, Reeves CA, Nicholas R, Carassiti D, Radotra B, Gentleman SM, Serafini B, Aloisi F, Roncaroli F, Magliozzi R, Reynolds Ret al., 2011, Meningeal inflammation is widespread and linked to cortical pathology in multiple sclerosis, BRAIN, Vol: 134, Pages: 2755-2771, ISSN: 0006-8950

Journal article

Thapar A, Lane TRA, Pandey V, Shalhoub J, Malik O, Ellis M, Franklin IJ, Nicholas R, Davies AHet al., 2011, Internal jugular thrombosis post venoplasty for chronic cerebrospinal venous insufficiency, PHLEBOLOGY, Vol: 26, Pages: 254-256, ISSN: 0268-3555

Journal article

Reynolds R, Roncaroli F, Nicholas R, Radotra B, Gveric D, Howell Oet al., 2011, The neuropathological basis of clinical progression in multiple sclerosis, ACTA NEUROPATHOLOGICA, Vol: 122, Pages: 155-170, ISSN: 0001-6322

Journal article

Bentley P, Wang T, Malik O, Nicholas R, Ban M, Sawcer S, Sharma Pet al., 2011, CADASIL with cord involvement associated with a novel and atypical NOTCH3 mutation, JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, Vol: 82, Pages: 855-860, ISSN: 0022-3050

Journal article

Friede T, Parsons N, Stallard N, Todd S, Marquez EV, Chataway J, Nicholas Ret al., 2011, Designing a seamless phase II/III clinical trial using early outcomes for treatment selection: An application in multiple sclerosis, 6th International Meeting on Statistical Methods in Biopharmacy, Publisher: WILEY, Pages: 1528-1540, ISSN: 0277-6715

Conference paper

Giannetti P, Politis M, Su P, Turkheimer F, Wu K, Reynolds R, Nicholas R, Piccini Pet al., 2011, Two different roles for microglia in vivo in T1 black holes in relapsing and progressive multiple sclerosis?, 21st Meeting of the European-Neurological-Society, Publisher: SPRINGER HEIDELBERG, Pages: 221-221, ISSN: 0340-5354

Conference paper

Wakerley BR, Nicholas RS, Malik OR, Altmann DMet al., 2011, The Effects of Disease Activity and Interferon-beta on Telomere Length and Telomerase Activity in Multiple Sclerosis, 63rd AAN Annual Meeting, Publisher: LIPPINCOTT WILLIAMS & WILKINS, Pages: A135-A135, ISSN: 0028-3878

Conference paper

Howell OW, Reeves C, Carassiti D, Nicholas R, Radotra B, Gentleman S, Roncaroli F, Aloisi F, Magliozzi R, Reynolds Ret al., 2011, The distribution of B-cell follicle-like structures in the cerebral meninges and their association with extensive inflammation and demyelination in multiple sclerosis, 112th Meeting of the British-Neuropathological-Society, Publisher: WILEY-BLACKWELL PUBLISHING, INC, Pages: 27-27, ISSN: 0305-1846

Conference paper

Chataway J, Nicholas R, Todd S, Miller DH, Parsons N, Valdes-Marquez E, Stallard N, Friede Tet al., 2011, A novel adaptive design strategy increases the efficiency of clinical trials in secondary progressive multiple sclerosis, MULTIPLE SCLEROSIS JOURNAL, Vol: 17, Pages: 81-88, ISSN: 1352-4585

Journal article

Nicholas R, Giannetti P, Alsanousi A, Friede T, Muraro PAet al., 2011, Development of oral immunomodulatory agents in the management of multiple sclerosis., Drug Des Devel Ther, Vol: 5, Pages: 255-274

The emergence of oral disease-modifying therapies in multiple sclerosis (MS) will have a significant impact on the evolving scenario of immunomodulatory treatments in MS where current therapies are all injectable. Reducing relapses in trials translates for individuals with MS into a therapeutic aim of stopping future events. Thus the possible absence of any perceived benefits to the individual together with the long disease course, variable outcome, and a younger age group affected in MS makes side effects the major issue. The use of disease-modifying therapies as a whole needs to be placed in the context of a widening therapeutic indication where the use of these therapies is being justified at an increasingly early stage and in pre-MS syndromes such as clinically isolated and radiologically isolated syndromes where no fixed disability is likely to have accumulated. The five oral therapies discussed (cladribine, fingolimod, laquinimod, BG-12, and teriflunomide) have just completed Phase III studies and some have just been licensed. New oral drugs for MS need to be placed within this evolving marketplace where ease of delivery together with efficacy and side effects needs to be balanced against the known issues but also the known long-term safety of standard injectables.

Journal article

Harris AJ, Durrenberger P, Kamel F, Ettorre A, Nicholas R, Malik O, Altmann DMet al., 2010, Investigating the role of natural killer cell subsets in multiple sclerosis, Annual Congress of the British-Society-for-Immunology, Publisher: WILEY-BLACKWELL PUBLISHING, INC, Pages: 125-125, ISSN: 0019-2805

Conference paper

Nicholas R, D'Arcy C, Muraro P, McGuigan C, Malik O, Giannetti P, O'Driscoll Set al., 2010, USING NATALIZUMAB IN HIGHLY ACTIVE RELAPSING REMITTING MULTIPLE SCLEROSIS IN THE UK, Annual Meeting of the Association-of-British-Neurologists, Publisher: B M J PUBLISHING GROUP, Pages: E53-E53, ISSN: 0022-3050

Conference paper

Friede T, Nicholas R, Stallard N, Todd S, Parsons N, Valdes-Marquez E, Chataway Jet al., 2010, Refinement of the Clinical Scenario Evaluation Framework for Assessment of Competing Development Strategies With an Application to Multiple Sclerosis, DRUG INFORMATION JOURNAL, Vol: 44, Pages: 713-718, ISSN: 0092-8615

Journal article

Nicholas R, Young C, Friede T, 2010, Bladder symptoms in multiple sclerosis: a review of pathophysiology and management, EXPERT OPINION ON DRUG SAFETY, Vol: 9, Pages: 905-915, ISSN: 1474-0338

Journal article

Magliozzi R, Howell OW, Reeves C, Roncaroli F, Nicholas R, Serafini B, Aloisi F, Reynolds Ret al., 2010, A Gradient of Neuronal Loss and Meningeal Inflammation in Multiple Sclerosis, ANNALS OF NEUROLOGY, Vol: 68, Pages: 477-493, ISSN: 0364-5134

Journal article

Mattoscio M, Nicholas R, Malik O, Mc Guigan C, Dazzi F, Muraro PAet al., 2010, Functional relevance of haematopoietic stem cell mobilization following therapeutic alpha 4-integrin blockade in multiple sclerosis: preliminary data, 20th Meeting of the European-Neurological-Society, Publisher: SPRINGER HEIDELBERG, Pages: S221-S221, ISSN: 0340-5354

Conference paper

Anderson JM, Patani R, Reynolds R, Nicholas R, Compston A, Spillantini MG, Chandran Set al., 2010, Abnormal tau phosphorylation in primary progressive multiple sclerosis, ACTA NEUROPATHOLOGICA, Vol: 119, Pages: 591-600, ISSN: 0001-6322

Journal article

Nicholas R, Radotra B, Roncaroli F, Reynolds Ret al., 2010, Increasing Macroscopic Pathological Damage in Multiple Sclerosis (MS) Is Associated with More Severe Disease Milestones, 62nd Annual Meeting of the American-Academy-of-Neurology, Publisher: LIPPINCOTT WILLIAMS & WILKINS, Pages: A365-A365, ISSN: 0028-3878

Conference paper

Politis M, Giannetti P, Su P, Turkheimer F, Keihaninejad S, Wu K, Waldman A, Reynolds R, Nicholas R, Piccini Pet al., 2010, Cortical Microglial Activation Is Associated with Disability in Secondary Progressive Multiple Sclerosis: An In Vivo Imaging Study, 62nd Annual Meeting of the American-Academy-of-Neurology, Publisher: LIPPINCOTT WILLIAMS & WILKINS, Pages: A290-A290, ISSN: 0028-3878

Conference paper

Marini-Bettolo C, Lane R, Charles P, Naresh K, Nicholas R, Singh P, Cohen A, Mackie P, Roncaroli Fet al., 2009, Myopathy secondary to intravascular large B-cell lymphoma, NEUROMUSCULAR DISORDERS, Vol: 19, Pages: 856-859, ISSN: 0960-8966

Journal article

Chataway J, Nicholas R, Stallard N, Todd S, Parsons N, Valdes-Marquez E, Friede Tet al., 2009, DEVELOPING A NEW TRIAL DESIGN IN SECONDARY PROGRESSIVE MULTIPLE SCLEROSIS: A SEAMLESS ADAPTIVE APPROACH, ABN Joint Annual Meeting/Spanish-Society-of-Neurology, Publisher: B M J PUBLISHING GROUP, ISSN: 0022-3050

Conference paper

Wakerley BR, Hanspall M, Malik O, Nicholas R, McGuigan Cet al., 2009, REASSESSING THE USE OF MITOXANTRONE IN MULTIPLE SCLEROSIS, ABN Joint Annual Meeting/Spanish-Society-of-Neurology, Publisher: B M J PUBLISHING GROUP, ISSN: 0022-3050

Conference paper

Chataway J, Nicholas R, Todd S, Stallard N, Valdes-Marquez E, Parsons N, Friede Tet al., 2009, Adaptive seamless trial designs in neurology: a case study in secondary progressive multiple sclerosis, 19th World Congress of Neurology, Publisher: ELSEVIER SCIENCE BV, Pages: S113-S114, ISSN: 0022-510X

Conference paper

Howell OW, Reeves C, Magliozzi R, Carassiti D, Nicholas R, Radotra B, Gentlemen S, Roncaroli F, Aloisi F, Reynolds Ret al., 2009, The incidence of meningeal B-cell follicles in secondary progressive multiple sclerosis: a neuropathological study of 96 cases, 25th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis, Publisher: SAGE PUBLICATIONS LTD, Pages: S5-S5, ISSN: 1352-4585

Conference paper

Nicholas R, Chataway J, Todd S, Stallard N, Valdes-Marquez E, Parsons N, Friede Tet al., 2009, Adaptive clinical trials incorporating treatment selection and evaluation: methodology and application in progressive multiple sclerosis, 25th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis, Publisher: SAGE PUBLICATIONS LTD, Pages: S142-S143, ISSN: 1352-4585

Conference paper

Magliozzi R, Howell OW, Durrenberger PF, Nicholas R, Roncaroli F, Aloisi F, Reynolds Ret al., 2009, Cell and molecular changes in the grey matter of secondary progressive multiple sclerosis cases in response to meningeal inflammation, 25th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis, Publisher: SAGE PUBLICATIONS LTD, Pages: S174-S174, ISSN: 1352-4585

Conference paper

Nicholas R, Chataway J, 2009, Multiple sclerosis., BMJ Clin Evid, Vol: 2009

INTRODUCTION: Multiple sclerosis is the most common cause of neurological disability in young adults. Irreversible disability can occur, but life expectancy is generally not affected. METHODS AND OUTCOMES: We conducted a systematic review and aimed to answer the following clinical questions: What are the effects of interventions aimed at reducing relapse rates and disability in people with multiple sclerosis? What are the effects of interventions to improve symptoms during acute relapse? What are the effects of treatments for fatigue, spasticity, and multidisciplinary care on disability in people with multiple sclerosis? We searched: Medline, Embase, The Cochrane Library, and other important databases up to June 2008 (Clinical Evidence reviews are updated periodically, please check our website for the most up-to-date version of this review). We included harms alerts from relevant organisations such as the US Food and Drug Administration (FDA) and the UK Medicines and Healthcare products Regulatory Agency (MHRA). RESULTS: We found 68 systematic reviews, RCTs, and observational studies that met our inclusion criteria. We performed a GRADE evaluation of the quality of evidence for interventions. CONCLUSIONS: In this systematic review, we present information relating to the effectiveness and safety of the following key interventions: amantadine, azathioprine, behaviour modification, botulinum toxin, corticosteroids, exercise, gabapentin, inpatient or outpatient rehabilitation, interferon beta, intrathecal baclofen, intravenous immunoglobulin, methotrexate, mitoxantrone, modafinil, natalizumab, oral drug treatments, parenteral glatiramer acetate, physiotherapy, and plasma exchange.

Journal article

This data is extracted from the Web of Science and reproduced under a licence from Thomson Reuters. You may not copy or re-distribute this data in whole or in part without the written consent of the Science business of Thomson Reuters.

Request URL: http://wlsprd.imperial.ac.uk:80/respub/WEB-INF/jsp/search-html.jsp Request URI: /respub/WEB-INF/jsp/search-html.jsp Query String: id=00412643&limit=30&person=true&page=6&respub-action=search.html